MESO — Mesoblast Limited stock price, charts and financials

QT47Mesoblast Limited

Mesoblast Limited (NASDAQ: MESO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.62
+0.68+4.29%
OverviewShort InterestFilings
MESOQT47Mesoblast Limited·NASDAQ
16.62+4.29%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ZBIO-0.99%$32.11AUPH-1.99%$15.54GHRS-1.53%$29.81OCUL+0.27%$9.21TSHA-1.60%$6.46STOK-1.35%$32.27ABCL+36.00%$9.43VRDN-2.48%$23.00
Snapshot
Index-P/E-EPS (ttm)-0.72Insider Own10.98%Shs Outstand129.70MPerf Week12.49%
Market Cap2.04BForward P/E20.95EPS next Y0.76Insider Trans59.75%Shs Float83.68MPerf Month7.48%
Enterprise Value2.05BPEG-EPS next Q-0.07Inst Own-Short Float3.74%Perf Quarter7.70%
Income-94.68MP/S31.28EPS this Y100.65%Inst Trans-Short Ratio16.07Perf Half Y-0.87%
Sales65.38MP/B3.54EPS next Y16136.02%ROA-12.06%Short Interest3.13MPerf YTD-11.64%
Book/sh-P/C-EPS next 5Y630.94%ROE-16.10%52W High22.42 -25.86%Perf Year1.79%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-20.16%52W Low13.20 25.91%Perf 3Y99.75%
Dividend Est.-EV/EBITDA-Sales past 3/5Y19.35% -11.88%Gross Margin-53.34%Volatility2.19% 3.30%Perf 5Y13.86%
Dividend TTM-EV/Sales31.36EPS Y/Y TTM19.10%Oper. Margin-223.08%ATR (14)0.64Perf 10Y87.97%
Dividend Ex-Date-Quick Ratio1.41Sales Y/Y TTM1000.00%Profit Margin-144.33%RSI (14)56.71Recom2.73
Dividend Gr. 3/5Y-Current Ratio1.58EPS Q/Q-11.07%SMA201.28%Beta2.08Target Price11.50
Payout0.00%Debt/Eq0.24Sales Q/Q1200.00%SMA506.71%Rel Volume0.38Prev Close15.94
Employees81LT Debt/Eq0.12EarningsSep 04SMA200-0.50%Avg Volume214.02KPrice16.62
IPO DateJan 20, 2010Option/ShortYes / YesEPS/Sales Surpr.-310.01% 75.83%Net Debt/EBITDA-0.09Volume80,929Change4.29%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-25-25UpgradeJefferiesHold → Buy
Jul-18-25DowngradeJefferiesBuy → Hold
Dec-23-24DowngradeJefferiesBuy → Hold
Sep-24-24ReiteratedMaxim GroupHold$12
Jul-23-24UpgradePiper SandlerNeutral → Overweight$11
Aug-30-23UpgradeJefferiesHold → Buy
Aug-06-23DowngradeMaxim GroupBuy → Hold
Aug-03-23DowngradePiper SandlerOverweight → Neutral
Aug-03-23DowngradeWilliam BlairOutperform → Market Perform
Dec-05-22DowngradeJefferiesBuy → Hold
Latest News
Jul-29-26
Jul-29-2608:57PM
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launchglobenewswire.com
Jul-17-26
Jul-17-2601:01PM
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?zacks.com
Jul-14-26
Jul-14-2604:48PM
A Fresh Look At Syndax PharmaceuticalsSeekingAlpha
Jul-13-26
Jul-13-2608:35PM
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Painglobenewswire.com
Jul-11-26
Jul-11-2607:59AM
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesisseekingalpha.com
Jul-09-26
Jul-09-2608:30PM
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026globenewswire.com
Jul-06-26
Jul-06-2601:35PM
8 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga
Jun-30-26
Jun-30-2608:38PM
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADsglobenewswire.com
Jun-29-26
Jun-29-2601:35PM
10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga
Jun-26-26
Jun-26-2608:03AM
ON Semiconductor, SanDisk And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga
Company

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
FY 2018
6/30/2018
Total Revenue66176——————
Cost of Goods Sold Incl. D&A100541——————
Gross Profit-3412-35——————
Selling, General and Administrative Excl. Other503924——————
Research and Development603525——————
Other Operating Expense010——————
Operating Income-146-62-84——————
Interest Expense02321——————
Unusual Expense
—————————
Non-Operating Income (Expense)52-1617——————
Net Income Before Taxes-94-102-88——————
Income Taxes
000——————
Consolidated Net Income-94-102-88——————
Net Income From Continuing Operations-94-102-88——————
Net Income-94-102-88——————
EPS (Recurring)-0.72-0.84-0.89——————
EPS (Basic, Before Extraordinaries)-0.72-0.84-0.89——————
EPS (Diluted)-0.72-0.84-0.89——————
EBITDA-66-74-56——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio32.4977.51112.37——————
Gross Margin-51.5270.59-583.33——————
Operating Margin-221.21-364.71-1,400.00——————
Net Margin-142.42-600.00-1,466.67——————
Shares Outstanding12912199——————
Market Capitalization2,1451,318674——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$22.58$19.07$15.56$12.05$8.54● Close Price0.00M4.99M9.97M14.96M19.95MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
George Gregorydirector, 10 percent owner:Apr 09 '26Buy4.962,181,89010,829,56413,586,890Apr 13
George Gregorydirector, 10 percent owner:Apr 10 '26Buy1.482,324,0723,439,6278,324,072Apr 10
George Gregorydirector, 10 percent owner:Apr 04 '26Buy1.424,000,0005,680,00012,000,000Apr 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.